[1]
|
Roberts, R.D., Lizardo, M.M., Reed, D.R., et al. (2019) Provocative Questions in Osteosarcoma Basic and Translational Biology: A Report from the Children’s Oncology Group. Cancer, 125, 3514-3525.
https://doi.org/10.1002/cncr.32351
|
[2]
|
Cersosimo, F., Lonardi, S., Bernardini, G., et al. (2020) Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. International Journal of Molecular Sciences, 21, 5207. https://doi.org/10.3390/ijms21155207
|
[3]
|
Isakoff, M.S., Bielack, S.S., Meltzer, P., et al. (2015) Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. Journal of Clinical Oncology, 33, 3029-3035. https://doi.org/10.1200/JCO.2014.59.4895
|
[4]
|
曹莉莉, 朱岩, 樊根涛, 等. 骨肉瘤的治疗进展[J]. 中国骨与关节杂志, 2020, 9(10): 771-778.
|
[5]
|
Thanindratarn, P., Dean, D.C., Nelson, S.D., et al. (2019) Advances in Immune Checkpoint Inhibitors for Bone Sarcoma Therapy. Journal of Bone Oncology, 15, Article ID: 100221. https://doi.org/10.1016/j.jbo.2019.100221
|
[6]
|
Chen, C.L., Zhang, L., Jiao, Y.R., et al. (2019) miR-134 Inhibits Osteosarcoma Cell Invasion and Metastasis through Targeting MMP1 and MMP3 in Vitro and in Vivo. FEBS Letters, 593, 1089-1101.
https://doi.org/10.1002/1873-3468.13387
|
[7]
|
Wedekind, M.F., Wagner, L.M., Cripe, T.P. (2018) Immunotherapy for Osteosarcoma: Where Do We Go from Here? Pediatric Blood & Cancer, 65, e27227. https://doi.org/10.1002/pbc.27227
|
[8]
|
Xu, J., Xie, L. and Guo, W. (2018) PDGF/PDGFR Effects in Osteosar-coma and the “Add-On” Strategy. Clinical Sarcoma Research, 8, 15. https://doi.org/10.1186/s13569-018-0102-1
|
[9]
|
Satomi, Y. and Tomoo, I. (2018) Regulators of Oncogenic Mutant TP53 Gain of Function. Cancers (Basel), 11, 4.
https://doi.org/10.3390/cancers11010004
|
[10]
|
Horio, Y., Takahashi, T., Kuroishi, T., et al. (1993) Prognostic Sig-nificance of p53 Mutations and 3P Deletions in Primary Resected Non-Small Cell Lung Cancer. Cancer Research, 53, 1-4.
|
[11]
|
Mclaren, R., Kuzu, L., Dunmil, M., et al. (1992) The Relationship of p53 Immunostaining to Survival in Car-cinoma of the Lung. British Journal of Cancer, 66, 735-738. https://doi.org/10.1038/bjc.1992.348
|
[12]
|
Quinlain, D.C., Davidson, A.G., Summers, C.L., et al. (1994) Accumulation p53 Protein Correlates with a Poor Prognosis in Lung Cancer. Cancer Research, 52, 4828-4834.
|
[13]
|
成秀梅. 肿瘤抑制基因p53的研究进展[J]. 现代诊断与治疗, 2008, 19(3): 158-160.
|
[14]
|
Yang, J., Li, Y.H., He, M.T., et al. (2020) HSP90 Regulates Osteosarcoma Cell Apoptosis by Targeting the p53/TCF- 1-Mediated Transcriptional Network. Journal of Cellular Physiology, 235, 3894. https://doi.org/10.1002/jcp.29283
|
[15]
|
Weinberg, R.L., Freund, S.M., Veprintsev, D.B., et al. (2004) Regulation of DNA Binding of p53 by Its C-Terminal Domain. Journal of Molecular Biology, 342, 801-811. https://doi.org/10.1016/j.jmb.2004.07.042
|
[16]
|
刘民培, 吴祖泽. 肿瘤基因的一种新的功能分类与概念[J]. 中国肿瘤临床, 2004, 31(21): 1253-1256.
|
[17]
|
Chen, Y.Q., Yang, T.Q., Zhou, B., et al. (2019) HOXA5 Overexpression Promotes Osteosarcoma Cell Apoptosis through the p53 and p38α MAPK Pathway. Gene, 689, 18. https://doi.org/10.1016/j.gene.2018.11.081
|
[18]
|
李文娟, 潘庆杰, 李美玉. p53基因及其功能研究进展[J]. 生物技术通讯, 2014, 25(2): 282-285.
|
[19]
|
于英君, 张庆梅, 郭丽新, 等. 树舌多糖GF对HepA瘤细胞Tp53基因表达的影响[J]. 中医药学报, 2002, 30(2): 56.
|
[20]
|
Dumont, P., Leu, I.J., Della Pietra, A.C., et al. (2003) The Codon 72 Polymorphic Variants of p53 Have Markedly Different Apoptotic Potential. Nature Genetics, 33, 357. https://doi.org/10.1038/ng1093
|
[21]
|
张立智. 蔡宣松p53基因治疗在骨肉瘤中的应用及展望[J]. 同济大学学报, 2002, 23(5): 435-441.
|
[22]
|
Guo, W., Wang, X. and Feng, C. (1996) p53 Gene Abnormalities in Osteosarconia. Chinese Medical Journal (England), 109, 752-755.
|
[23]
|
Liu, S., Yue, J., Du, W., et al. (2018) LAMP3 Plays an Onco-genic Role in Osteosarcoma Cells Partially by Inhibiting TP53. Cellular & Molecular Biology Letters, 23, Article No. 33. https://doi.org/10.1186/s11658-018-0099-8
|
[24]
|
Toguchida, J., Yamaguchi, T., Ritchie, B., et al. (1992) Mutation Spectrum of the p53 Gene in Bone and Soft Tissue Sarcomas. Cancer Research, 52, 6194-6199.
|
[25]
|
Tataria, M., Quarto, N., Longaker, M.T., et al. (2006) Absence of the p53 Tumor Suppressor Gene Promotes Osteogenesis in Mes-enchymal Stem Cells. Journal of Pediatric Surgery, 41, 624-632.
https://doi.org/10.1016/j.jpedsurg.2005.12.001
|
[26]
|
Van Leeuwenna, I.S., Comelisse, C.J., Misdorp, W., et al. (1997) P53 Gene Mutations in Osteosarcomas in the Dog. Cancer Letters, 111, 173-178. https://doi.org/10.1016/S0304-3835(96)04529-6
|
[27]
|
Johnson, A.S., Couto, C.G., Weghorst, C.M. (1998) Muta-tion of the p53 Tumor Suppressor Gene in Spontaneously Occurring Osteosarcomas of the Dog. Carcinogenesis, 19, 213-721. https://doi.org/10.1093/carcin/19.1.213
|
[28]
|
Grote, H.J., Schneider-Stock, R., Neumann, W., et al. (2000) Mutation of p53 with Loss of Heterozygosity in the Osteosarcomatous Component of a Dedifferentiated Chondrosar-coma. Virchows Archiv, 436, 494-497.
https://doi.org/10.1007/s004280050478
|
[29]
|
Ganjavi, H., Gee, M., Narendran, A., et al. (2006) Adenovi-rus-Mediated p53 Gene Therapy in Osteosarcoma Cell Lines: Sensitization to Cisplatin and Doxorubicin. Cancer Gene Therapy, 13, 415-419.
https://doi.org/10.1038/sj.cgt.7700909
|
[30]
|
Goto, A., Kanda, H., Ishikawa, Y., et al. (1998) Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in Osteosarcomas. Japanese Journal of Cancer Research, 89, 539-547.
https://doi.org/10.1111/j.1349-7006.1998.tb03295.x
|
[31]
|
Asada, N., Tsuchiva, H., Tomita, K. (1999) De Novo Deletions of p53 Gene and Wild-Type p53 Correlate with Acquired Cisplatin-Resistance in Hunan Osteosarcoma OST Cell Lime. Anticancer Research, 19, 5131-5137.
|
[32]
|
Bacci, G., Longhi, A., Versari, M., et al. (2006) Prognostic Fac-tors for Osteosarcoma of the Extremity Treated with Neoadjuvant Chemotherapy: 15-Year Experience in 789 Patients Treated at a Single Institution. Cancer, 106, 1154-1161.
https://doi.org/10.1002/cncr.21724
|
[33]
|
Truchiva, H., Mori, Y., Ueda, Y., et al. (2000) Sensitization and Caffeine Potentiation of Cisplatin Cytotoxicity Resulting from Introduction of Wild-Type p53 Gene in Human Osteosarcoma. An-ticancer Research, 20, 235-242.
|
[34]
|
Wang, L.H., Okaichi, K., Ihara, M., et al. (1998) Sensitivity of Anticancer Drugs in Saos-2 Cells Transfected with Mutant p53 Varied with Mutation Point. Anticancer Research, 18, 321-325. https://doi.org/10.1269/jrr.39.111
|
[35]
|
许伟, 丁聚贤, 谢兴文, 李鼎鹏, 李宁, 柳博, 苏积亮, 李建国, 宋学文. 肉苁蓉对化疗耐药骨肉瘤细胞的逆转作用及MRP1、P53表达的影响[J]. 时珍国医国药, 2021, 32(3): 551-554.
https://doi.org/10.3969/j.issn.1008-0805.2021.03.11
|
[36]
|
林晋, 唐风华, 黄铭珊, 许颖, 黄志鸿. 褪黑素对人骨肉瘤细胞p53、c-Myc表达的影响[J]. 海峡药学, 2020, 32(6): 6-9.
|
[37]
|
胡文姝, 李伟. 柚皮素通过p53-MDM2信号通路对人骨肉瘤SJSA-1细胞增殖及周期的影响[J]. 辽宁中医杂志, 2022, 49(6): 23-27+223. https://doi.org/10.13192/j.issn.1000-1719.2022.06.005
|
[38]
|
谭瑞, 段伟, 王子君, 袁鹏, 常乐, 甘璐, 权鹏鹤, 史喜德, 李沫, 叶正旭. FIS1通过P53通路抑制骨肉瘤对顺铂化疗的耐药[J]. 临床与病理杂志, 2021, 41(10): 2231-2238. https://doi.org/10.3978/j.issn.2095-6959.2021.10.002
|
[39]
|
潘珍. 壳寡糖通过激活骨肉瘤中p53/mTOR途径抑制肿瘤进展并诱导自噬的机制研究[D]: [硕士学位论文]. 上海: 上海交通大学, 2020. https://doi.org/10.27307/d.cnki.gsjtu.2020.002838
|
[40]
|
Li, B., Chan, H.L. and Chen, P. (2019) Immune Check-point Inhibitors: Basics and Challenges. Current Medicinal Chemistry, 26, 3009-3025. https://doi.org/10.2174/0929867324666170804143706
|
[41]
|
Julianna, B. and Michael, D.B. (2020) p53, Cancer and the Immune Response. Journal of Cell Science, 133, jcs237453.
|
[42]
|
Long, J., Wang, A., Bai, Y., et al. (2019) De-velopment and Validation of a TP53-Associated Immune Prognostic Model for Hepatocellular Carcinoma. eBioMedicine, 42, 363-374. https://doi.org/10.1016/j.ebiom.2019.03.022
|
[43]
|
Nie, K., Zheng, Z., Wen, Y., et al. (2020) Construc-tion and Validation of a TP53-Associated Immune Prognostic Model for Gastric Cancer. Genomics, 112, 4788-4795. https://doi.org/10.1016/j.ygeno.2020.08.026
|
[44]
|
Benjamin, S., Richard, J.Y., Danny, R. (2019) Correlate the TP53 Mutation and the HRAS Mutation with Immune Signatures in Head and Neck Squamous Cell Cancer. Computational and Structural Biotechnology Journal, 17, 1020-1030. https://doi.org/10.1016/j.csbj.2019.07.009
|
[45]
|
郭梅, 李渝华, 荆安龙. 儿童骨肉瘤中TP53突变与免疫分子基因表达的相关性分析[J]. 现代肿瘤医学, 2022, 30(15): 2837-2841. https://doi.org/10.3969/j.issn.1672-4992.2022.15.031
|
[46]
|
Nishikawa, T., Yamamoto, T., Mizuno, K., et al. (1997) Expression of the p53 Protein in Human Osteosarcoma. Nippon Seikeigeka Gakkai Zasshi, 68, 400-406.
|
[47]
|
Papai, Z., Feja, L.N., Hanna, E.N., et al. (1997) P53 Overexpression as an Indicator of Overall Survival and Response to Treatment in Osteosarcomas. Pathology and Oncology Research, 3, 15-19. https://doi.org/10.1007/BF02893346
|
[48]
|
Wadayama, B., Toguchida, J., Tamaguchi, T., et al. (1993) p53 Expres-sion and Its Relationship to DNA Alterations in Bone and Soft Tissue Sarcomas. British Journal of Cancer, 68, 1134-1139. https://doi.org/10.1038/bjc.1993.493
|
[49]
|
Radig, K., Schneide, R., Stock, R., Haeckel, C., et al. (1998) p53 Gene Mutations in Osteosarcomas of Low-Grade Malignancy. Human Pathology, 29, 1310-1316. https://doi.org/10.1016/S0046-8177(98)90263-5
|